

Covid-19: Summary of Current Clinical Evidence for GPs and Frontline Clinicians

Updated 22 July 2020

Version 14

This is a summary of the current evidence around Covid-19, caused by the SARS-Cov2 virus.

The purpose of this document is to provide supplemental information regarding Covid-19 that is not readily accessible and available from DDHS Victoria Guidelines, or Department of Health (Australian Federal) Guidelines relating to Covid-19.

It is hoped that this information will help to shape and inform our response in our individual contexts.

Updates

Pregnant women with Covid 19 are more likely than non-pregnant women to be hospitalised, admitted to the ICU and placed on mechanical ventilation. (page 3)

Case fatality rate (CFR) by age

Age	CFR (China Data³ 72,314 cases)	CFR (Italy Data 25,058 cases)²¹
>90 years old		21.6%
> 80 years old	14.8%	18.8%
70-79 years old	8.0%	11.8%
60-69 years old	3.6%	3.2%
50-59 years old	1.3%	1.0%
40-49 years old	0.4%	0.3%
10-39 years old	0.2%	
0-9 years old	No fatalities	

Case fatality rate by gender (based on China Data³)

- Male 2.8%
- Female 1.7%

Risk Factors (based on China Data³)

1. Cardiovascular disease (case fatality rate 10.5%)
2. Diabetes (CFR 7.3%)

3. Chronic respiratory disease (CFR 6.3%)
4. Hypertension (CFR 6.0%)
5. Cancer (CFR 5.6%)

Children:

Clinical disease is generally less severe than in adult patients. However, young children, particularly infants (<1yo) may be vulnerable to infection.

Based on a [study](#)¹⁴ of 2,143 paediatric cases (suspected and confirmed) in China, the proportion of severe and critical cases are as follows:

<1 years old	10.6%
1-5 years old	7.3%
6-10 years old	4.2%
11-15 years old	4.1%
>16 years old	3.0%

Nevertheless, overall there was a relatively small number of children reported from a paediatric population of several million. In addition, the proportion of severe and critical cases in children <18 years of age was 5.9%, compared to adult patients (18.5%).

Paediatric Multisystem Inflammatory Syndrome (PIMS)

Believed to be a post-infectious manifestation of Covid 19 infection in children.

In a French case series of 108 children³⁰, 67% required intensive care. There was one fatality. Researchers estimated the risk of PIMS to be fewer than 2 cases per 10,000 children.

WHO Preliminary Case Definition (published 15 May 2020)

Children and adolescents 0–19 years of age with fever \geq 3 days

AND two of the following:

1. Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet).
2. Hypotension or shock.
3. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP),
4. Evidence of coagulopathy (by PT, PTT, elevated d-Dimers).
5. Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain).

AND

Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin.

AND

No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

AND

Evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19.

Pregnancy:

Based on a US CDC report released on 26 June 2020¹¹, 31.5% of pregnant women with Covid 19 were hospitalised compared to 5.8% of non-pregnant women. Pregnant women were 50% more likely to be admitted to the ICU compared to non-pregnant women, and were 70% more likely to receive mechanical ventilation. This was based on data from 8,207 pregnant women and 83,205 non-pregnant women with Covid 19.

Overall CFR (based on 'China Data'): 2.3%

Summary of Case Fatality

Mortality is skewed towards an older population, and those with co-morbidities.

CFR rates vary depending on the preparedness of the country, social distancing policies and robustness of the health system.

In countries and health systems that are prepared and implement social distancing policies early, CFR is closer to 1%.

In countries that are unprepared, CFR can be between 3-5%

In comparison, the seasonal flu is estimated to be 0.1%.

Stratification (based on DDHS Vic Guidelines)

Two key groups of patients:

1. Those systemically well with mild coryzal symptoms (estimated to be 80-85% of cases)
2. Those systemically unwell with evidence of lower respiratory tract infection, and symptoms such as shortness of breath, fever and productive cough (estimated to be 15-20% of cases)

Incubation Period

Median is 5-6 days (0-14 day range). Longer incubation periods occasionally occur, but are considered 'outliers'.¹⁶

Key Symptoms

Given delays in diagnostic confirmation of influenza vs covid-19 in the GP setting, accurate differentiation of influenza vs covid-19 based on symptoms will be crucial.

An epidemiological [report](#)¹⁶ from the Australian Department of Health published on 3 Apr 2020 based on 2,257 confirmed cases (*non-hospitalised and hospitalised*) has revealed that key symptoms were:

More Common	Less Common
Cough (70%)	Runny nose (34%)
Fever (47%)	Muscle pain (32%)
Sore throat (45%)	Shortness of breath (22%)
Headache (49%)	Diarrhoea (18%)
	Nausea and Vomiting (15%)

Based on a study of *hospitalised* patients (N=138⁸) with Covid-19 in China the 10.1% of patients who initially presented with diarrhoea and nausea subsequently developed fever and dyspnoea 1-2 days later.

In comparison, in a study⁹ of >1,000 patients with influenza, key differentiating symptoms from Covid-19 are:

1. Nasal congestion (84-92%)
2. Myalgia (49-86%)

Therefore, it may be extrapolated that, patients with:

- **INFLUENZA** are *more likely to have rhinorrhoea, myalgias*

While patients with:

- **COVID 19** are *less likely to have rhinorrhea and myalgias*

Isolated anosmia is believed to be a significant symptom of Covid 19, based on anecdotal evidence from multiple countries around the world. In South Korea, 30% of positive patients are reported to have anosmia as their main presenting complaint. In Germany, it is believed that 2/3rds of positive cases have anosmia. See [letter](#) from ENT UK.

Clinical Progression

Patients may have mild symptoms in week one, before becoming systemically unwell in week two.

Those systemically unwell typically have clinical and radiological features of viral pneumonia¹.

Thereafter, patients may develop sepsis, acute respiratory distress syndrome (ARDS) or multi-organ failure^{1,4}.

The median time from onset of illness to hospitalisation for novel coronavirus pneumonia patients was seven days (range 4–8 days), with acute respiratory distress syndrome (ARDS) experienced on day eight (range 6–12 days)⁸.

ARDS has a mortality rate of 40%.

The mortality rate of Covid 19 patients on a ventilator is exceedingly high. Mortality rates reported from New York City was 88.1%²⁹, which is consistent with figures from Wuhan, China⁴ and Lombardy, Italy.

This highlights the importance of Advance Care Planning. An excellent resource is available from Advance Care Planning Australia (click [here](#)).

ICU Admission

Approximately 5% of symptomatic, confirmed cases require ICU admission.

Asymptomatic cases and transmission

Based on data from the Diamond Princess cruise ship, up to 50.5% of positive cases were asymptomatic at the time of testing. Sample size of 634 positive cases²³.

There are case reports of asymptomatic transmission of the virus, up to 48 hours before the onset of symptoms. The first known case report²² was published in NEJM on the German cluster on 30th January 2020.

A study²⁷ based in Singapore concluded that 6.4% of 157 cases of community transmission were from asymptomatic transmission. This underscores the importance of social distancing to reduce the spread of Covid 19.

DHHS Vic Guidelines consider a positive case to be infectious 48 hrs prior to the onset of symptoms, for the purpose of contact tracing.

Investigations

If patient fits criteria, send off one nasopharyngeal +/- throat swabs (use FLOQ swabs) for:

- Respiratory Multiplex PCR
- Coronavirus Covid-19

FBE demonstrates leucopenia in 25% of cases, and lymphopenia in 63% of cases.

Covid 19 Rapid IgG/IgM antibody tests. The Royal College of Pathologists in Australia have released a [strong statement](#) (1 Apr 2020) saying that these tests have no role in the acute diagnosis and early detection of Covid 19, as these tests rely on detecting antibodies to SARS-Cov2. Antibodies take 7-12 days to develop in a healthy individual, much longer in elderly and immunocompromised people.

These tests may have a role in detecting previously unrecognised infection and subsequent immunity, but that role has yet to be validated.

Co-infection

A preprint published on medRxiv²⁴ found that 5.8% of cases infected with COVID-19 were co-infected with other pathogens including, influenza, respiratory syncytial virus, rhinovirus, metapneumovirus, parainfluenza, chlamydia, boca virus, mycoplasma pneumoniae, and other species of coronaviruses.

Imaging Findings

CXR: unilateral (25%) or bilateral (75%) interstitial/ground glass infiltrates¹

In patients recovering from COVID-19 pneumonia (without severe respiratory distress during the disease course), lung abnormalities on chest CT showed greatest severity approximately *10 days* after initial onset of symptoms.²

In patients recovering from COVID-19 infection, four stages of evolution on chest CT were identified:

1. early stage (0-4 days);
2. progressive stage (5-8 days);
3. peak stage (10-13 days);
4. and absorption stage (≥ 14 days)

Complications of Covid 19

Non-respiratory complications have been reported, but are primarily confined to case series and case reports.

Thromboembolic disease

Case reports of thromboembolic disease, and stroke exist in the literature³³. As such, based on a risk vs benefit assessment, peak bodies in Australia recommend DVT prophylaxis with enoxaparin 40mg or dalteparin 5000 IU once daily in adults with moderate COVID-19 or other indications, unless there is a contraindication, such as risk for major bleeding.

Cardiac

A case report, published on 27 Mar 2020¹⁸ described an Italian woman who developed acute myopericarditis, without any respiratory symptoms or involvement throughout her clinical course.

A case series, published on 27 Mar 2020¹⁹ documented that 27.8% of a cohort of 187 patients developed evidence of myocardial injury based on elevated troponin levels. 16 patients did *not* have underlying cardiovascular disease, but had elevated troponin levels. Mortality rate of this sub-group was 37.5%. Overall mortality of the cohort of 187 patients was 23%, suggesting that a particularly unwell group of patients were recruited into this study.

Atypical Covid 19 patients may present with chest pain.

Gastrointestinal

A case series of 204 hospitalised patients²⁰ in China found that those with gastrointestinal symptoms (18.6%) had delays in their diagnosis and treatment. Almost 3% of this case series had gastrointestinal symptoms but no respiratory symptoms.

Atypical Covid 19 patients may present with diarrhoea, nausea, vomiting and rarely abdominal pain.

Management

Primarily supportive care.

Patients at risk of developing ARDS need to be in a facility where they can be mechanically ventilated, to improve their survival chances.

Two of Australia's peak bodies:

1. Australasian Society for Infectious Diseases (ASID)
2. Australian and New Zealand Intensive Care Society (ANZICS)

Have released guidelines on management Covid 19 patients.

These guidelines primarily recommend supportive care. Use of Remdesivir may be considered outside of a trial setting. Other therapies are only recommended in the context of a trial.

As of 3 Apr 2020, two multi-centre RCTs of antiviral therapies for COVID-19 are recruiting hospitalised patients in Australia and New Zealand: REMAP-CAP (endorsed by ANZICS), and ASCOT (endorsed by ASID).

Medications - Anti-inflammatories and ARBs

The use of anti-inflammatories, ie. ibuprofen is discouraged, based on anecdotal reports of serious disease in four young patients after using NSAIDs. See BMJ [commentary](#).

There has been controversy regarding Angiotensin Receptor Blockers (ARBs) in the Covid 19 pandemic. The reason is because:

1. The entry site for the SARS-Cov2 virus is ACE 2 (Angiotensin Converting Enzyme 2), of which Angiotensin 2 is a substrate
2. ARBs are known to increase ACE 2 expression by 3-5 fold, because plasma levels of Angiotensin 2 increases with ARB dosing.

Hence a theoretical risk that ARBs may increase one's vulnerability to Covid 19 infection.

However, there is currently no evidence linking ARBs with more severe outcomes in Covid 19.

Hence the strong recommendation from peak bodies, ie. Heart Foundation (Australia), and European Society of Cardiology for patients already on these medications to continue taking them.

Nevertheless, Professor Esler (senior director of the Baker Heart and Diabetes Institute), in the Journal of Hypertension¹⁷ suggests:

1. If on ARBs to remain on current dose and do not escalate the dose
2. Do not cease, as it may precipitate CCF or unstable blood pressure
3. If not on ARBs, consider other agents for hypertension control
4. Don't commence ARBs if not hypertensive

The role of ACE inhibitors is less clear, but ACE inhibitors reduce plasma levels of Angiotensin 2, and hence theoretically reduces ACE 2 expression.

Aerosol generating procedures (AGPs)

Aerosol generating procedures (AGPs) should be avoided where possible, as this may cause the virus to become airborne.

Nebuliser use should be discouraged and alternative administration devices (for example, spacers) should be used⁵.

Other examples of AGPs include: endo-tracheal intubation, non-invasive ventilation (BiPAP, CPAP, HFOV), manual ventilation before intubation (bag and mask), cardiopulmonary resuscitation, sputum induction, suctioning.

Patient placement

A dedicated toilet / commode should be used where possible, ensuring the lid is closed when flushed to reduce any risk of aerosolisation.

Persons under investigation and suspected cases of COVID-19 infection may be cohorted together where single rooms are not available.

Maintain a record of all persons entering the patient's room including all staff and visitors.

Environmental cleaning and disinfection

For all routine and discharge cleaning, after cleaning with a neutral detergent use a chlorine-based disinfectant (for example, sodium hypochlorite) at a minimum strength of 1000ppm²⁶, or other products with claims against coronaviruses. Examples are:

White King Bleach, sodium hypochlorite 4% chlorine may be diluted to 0.5% chlorine (5,000 ppm) to form a 'hospital-grade' intermediate-level disinfectant which will be bactericidal, virucidal, mycobactericidal, and sporicidal. Formula: 1 part bleach 4%, 7 parts water²⁵

Hydrogen Peroxide 0.5%

Ethanol 62-71% (Click [here](#)¹⁵ for source)

Coles and Woolworths stock products based on benzalkonium chloride. A minimum concentration of 0.05% is required. Click [here](#)¹³ and [here](#) for two international sources.

A one-step detergent/chlorine-based product may also be used.

The patient isolation room should be cleaned at least once daily and following any aerosol generating procedure (AGP) or other potential contamination.

Droplet and contact precautions (surgical mask, protective eyewear, gloves, gown) should be implemented during any cleaning and disinfection of a room.

Discharge cleaning

If there is a possibility that the virus may have become airborne because:

1. an aerosol generating procedure was performed (ie. nebuliser used)
2. severe symptoms suggestive of pneumonia

It is recommended that the room be left for 30 minutes before cleaning and disinfection is commenced.

The exact duration in which SARS-Cov2 can persist in the environment is unclear at this time, but the coronaviruses that caused SARS and MERS were able to persist in the environment for over 48 hours, at an average room temperature of 20 degrees celsius.

Recovery

Based on 391 cases in Shenzhen, China¹⁶, median time to recovery:

- 20-29 year olds: 27 days
- 50-59 year olds: 32 days
- >70 year olds: 36 days

Mutations and Immunity

According to a Chinese study of 103 cases¹², published on 3 Mar 2020, the SARS-Cov2 virus has mutated into two major subtypes: S and L.

Nevertheless, there is no clinical evidence that re-infection with the L subtype is possible in a person already immune to the S subtype (and vice versa).

A study into the persistence of the serological response post-infection showed that the serological response to SARS-Cov2 was short-lived. This study looked at 37 people infected with symptoms and 37 asymptomatic. 8 weeks after recovery, antibody levels fell to undetectable levels in 40% of asymptomatic people and 13% of symptomatic people²⁸. This is in stark contrast to SARS-CoV and MERS-CoV where circulating antibodies lasted for at least 1 year.

Similar studies on duration of serological responses based in the UK and Spain have produced similar results and conclusions.

Transmissibility post-recovery

Although there are case reports of patients testing positive post-recovery¹⁰, it is believed these are 'false positives' due to the detection of dead virions or viral fragments.

Nevertheless, the standard protocol is for 2 consecutive negative PCR tests, 24 hours apart, before someone is declared 'non-infectious'.

Possible Therapeutics under trial

1. Remdesivir. ACTT-1 trial: an international, multi-centre RCT of 1,063 patients showed that Remdesivir reduced recovery time in hospitalised patients with evidence of lower respiratory tract infection from 15 days to 11 days³¹.
2. Dexamethasone. An RCT based in the UK released a pre-print³⁴ of their findings. 2,104 patients received dexamethasone, compared with 4,321 patients who received standard

care. Dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; $p < 0.001$), by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; $p = 0.002$), but did not reduce mortality in patients not receiving respiratory support at randomization.

3. Lopinavir and Ritonavir - HIV medication. Had activity against SARS and MERS. As of 18 Mar 2020, an RCT trial with Lopinavir and Ritonavir has not demonstrated promise (see [trial](#)). However, it is believed that anti-virals were likely commenced too late in the course of the disease. Hence, trials are ongoing to commence anti-virals within 12 days of symptom onset.

Hydroxychloroquine (HCQ). On 17 June 2020, WHO announced that the hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment was being stopped. Data from Solidarity (including the French Discovery trial data) and the recently announced results from the UK's Recovery trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care.

Disclaimer

Written by a rural GP, for other GP colleagues and frontline clinicians. This document is not meant to replace authorised guidance from the department of health, or any formal health authority.

References

1. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. (Published 29 January 2020)
2. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia (Published 13 Feb 2020)
3. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (Covid-19) - China, 2020, *China CDC Weekly* (Published 17 Feb 2020)
4. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective observational study. *Lancet*. (Published 24 February 2020)
5. DDHS Victoria Coronavirus disease 2019 (COVID-19) Guideline for health services and general practitioners 1 Apr 2020 Version 16
6. COVID-19, Australia: Epidemiology Report 3: Reporting week ending 19:00 AEDT 15 February 2020. COVID-19 National Incident Room Surveillance Team
7. Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2 - ECDC technical report (accessed 28 Feb 2020)
8. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. (7 Feb 2020)
9. Clinical Characteristics and 30-Day Outcomes for Influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) Infections. *JAMA*. 8 Sept 2010
10. Positive RT-PCR Test Results in Patients Recovered From COVID-19. *JAMA*. (27 Feb 2020)
11. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–June 7, 2020. *CDC MMWR Vol 69, No 25*. 26 June 2020.
12. On the origin and continuing evolution of SARS-CoV-2. *National Science Review*. 3 Mar 2020

13. Interim List of Household Products and Active Ingredients for Disinfection of the COVID-19 Virus. NEA Singapore. Accessed 12 Mar 2020
14. Epidemiological characteristics of 2,143 pediatric patients with 2019 coronavirus disease in China. Pediatrics. Accessed 18 Mar 2020
15. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection. Mar 2020
16. Covid-19, Australia, Epidemiology Report (8 & 9), Communicable Diseases Intelligence (accessed 29 Mar, 3 Apr 2020)
17. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? M. Esler et al. Journal of hypertension. Mar 2020
18. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). Riccardo M et al. JAMA. 27 Mar 2020
19. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). Tao Gao et al. JAMA. 27 Mar 2020
20. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Lei Pan et al. American J of Gastroenterology (preprint - accessed 3 Apr 2020)
21. Johns Hopkins Centre for Health Security Covid 19 Newsletter. 17 Mar 2020
22. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. Camilla Rothe et al. NEJM. 30 Jan 2020
23. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Kenji Mizumoto et al. Eurosurveillance. 12 Mar 2020
24. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. Ming Wang et al. MedRxiv preprint doi: <https://doi.org/10.1101/2020.02.12.20022327>
25. Best Practices for Environmental Cleaning in Healthcare Facilities: in Resource-Limited Settings Version 1. Centres for Disease Control and Prevention (CDC). November 2019.
26. Environmental cleaning and disinfection principles for health and residential care facilities Version 2. Australian Department of Health. 26 Mar 2020.
27. Presymptomatic transmission of SARS-Cov2 - Singapore Jan 23 - Mar 16, 2020, Wei WE et al, CDC MMWR. 1 Apr 2020.
28. Clinical and immunological assessment of asymptomatic SARS-Cov2 infections. Quan-Xin Long et al. Nature Medicine. 18 June 2020.
29. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. S. Richardson et al. JAMA. 22 Apr 2020.
30. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. Alexandre Belot et al. Eurosurveillance, Volume 25, Issue 22. 4 June 2020.
31. Remdesivir for the Treatment of Covid-19 — Preliminary Report. John H Beigel et al. NEJM. 22 May 2020.
32. Multisystem inflammatory syndrome in children and adolescents with COVID-19. WHO Scientific Brief. 15 May 2020.
33. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Matthijs Oudkerk et al. Radiology. 2020
34. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. Peter W Horby et al. medRxiv preprint doi: <https://doi.org/10.1101/2020.06.22.20137273>.

Dr James S Wei, MBBS, BMedSci, DCH, FRACGP

General Practitioner, Standish Street Surgery

Myrtleford, Victoria, Australia

james.wei.standish@gmail.com

Published on: www.covid19forgps.com